Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products. It offers endocrinology products for the treatment of diabetes, osteoporosis in postmenopausal women and men, and human growth hormone deficiency and pediatric growth conditions. The Company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, schizophrenia, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and more.

Type
Public
HQ
Indianapolis, US
Founded
1876
Size (employees)
40,655 (est)-3%
Website
lilly.com
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information

Key People/Management at Eli Lilly

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer
Melissa Stapleton Barnes

Melissa Stapleton Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno

Enrique A. Conterno

Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry

Stephen F. Fry

Senior Vice President, Human Resources and Diversity
Michael J. Harrington

Michael J. Harrington

Senior Vice President and General Counsel
Susan Mahony

Susan Mahony

Senior Vice President and President, Lilly Oncology
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)
Report incorrect company information

Eli Lilly Financials and Metrics

Eli Lilly Revenue

Embed Graph
Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.
USD

Market capitalization (16-Aug-2018)

112.1 b

Closing stock price (16-Aug-2018)

104.4
Eli Lilly's current market capitalization is $112.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1 b19.6 b20 b21.2 b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
Quarterly
USDQ1, 2018

Revenue

5.7 b

Pre tax profit

1.4 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m

Inventories

2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
Quarterly
USDQ1, 2018

Current Liabilities

11.5 b

Additional Paid-in Capital

5.8 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
Quarterly
USDQ2, 2018

Depreciation and Amortization

848 m

Cash From Operating Activities

2 b
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AurKa Pharma May 15, 2018$575 m
ARMO BioSciences Inc May 11, 2018$1.60 b
CoLucid Pharmaceuticals January 18, 2017$960 m
Novartis Animal Health April 22, 2014$5.40 b
Avid Radiopharmaceuticals November 08, 2010$800 m
Alnara Pharmaceuticals July 02, 2010$280 m
Imclone Systems October 06, 2008$6.50 b
Report incorrect company information

Eli Lilly Online and Social Media Presence

Embed Graph
Report incorrect company information

Eli Lilly News and Updates

US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor

EXTON, Pa., Aug. 20, 2018 /PRNewswire/ -- Spherix Global Insights' third quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US) captured initial insights on Eli Lilly's long-awaited launch of Olumiant (baricitinib). While three-quarters of rheumatologists (n=99) are aware of the...

Eli Lilly to take animal health unit public, profit beats estimates

Eli Lilly and Co announced on Tuesday it would take its Elanco animal health business public and posted better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

Eli Lilly to spin off animal health unit, quarterly profit beats estimates

Eli Lilly and Co announced on Tuesday it would spin off its Elanco animal health business and posted better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

Eli Lilly spins off animal health unit, second quarter beats

Eli Lilly and Co on Tuesday said it would spin off its Elanco animal health business into a publicly-traded company and posted better-than-expected quarterly profit helped by demand for its diabetes drugs Trulicity and Humalog.

Eli Lilly posts quarterly loss

Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.
Show more
Report incorrect company information

Eli Lilly Company Life and Culture

Report incorrect company information